Japan· JP-3921001F1031
エデト酸カルシウムナトリウム水和物
A edetate product containing エデト酸カルシウムナトリウム水和物, registered in Japan by 日新製薬（山形）, on the national reimbursement list. The same ATC class is registered in 2 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Edetate is registered in 2 of 19 countries.
Countries holding a registration under ATC V03AB03 (edetate), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 1 of them publish a price we can compare per daily dose
Edetate · ATC V03AB03
2 / 19 countries
- Japan
- Norwayprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- エデト酸カルシウムナトリウム水和物
- Manufacturer
- 日新製薬（山形）
- Country
- Japan (JP)
- ATC code
- V03AB03
- ATC class
- Edetate
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
7 interactions on record for edetate.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Edetate · interactions on record
7 records
- 6 severe
- 1 moderate
Most severe, free to view
- IohexolV08AB02severe
- IopamidolV08AB04severe
- IopromideV08AB05severe
- IoversolV08AB07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Edetate in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayNatriumedetat SASykehusapoteket Oslo, Rikshospitalet
- GermanyNatriumedetat Smartpractice EuropeSmartpractice Europe Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Germany · Natriumedetat Smartpractice Europe
- France · Chelatran
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3a886d66-4849-4d5c-a880-1793ba022296 GET /v1/drugs/3a886d66-4849-4d5c-a880-1793ba022296?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５００ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3921001F1031",
"category": "内用薬",
"price_yen": 70.7,
"generic_name": "エデト酸カルシウムナトリウム水和物",
"product_name_jp": null,
"therapeutic_class": "3921",
"transitional_expiry": null
}See everything about edetate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.